Show notes
The global peptide supplement market hit $4.1 billion in 2025 and is projected to reach $11.2 billion by 2035. Instagram influencers, Silicon Valley biohackers, and MAHA movement figures are all talking about them. Your patients are asking about them constantly. And the regulatory landscape just changed dramatically — in April 2026, RFK Jr. announced the removal of 12 peptides including BPC-157, TB-500, and GHK-Cu from the FDA's restricted Category 2 list, with an advisory panel convening in July 2026 to formally consider adding them back to the legal compounding list.
This episode is the…
Website: podcasters.spotify.com

